Amgen’s experimental KRAS-blocking drug is showing minimal tumor-shrinking effects in patients with advanced colorectal cancer, raising new doubts about whether the drug can be broadly effective against different types of solid tumors.
The drug, known as AMG 510, has generated significant interest since the release of data showing its potential to shrink tumors in lung cancer patients. But data presented Saturday at this year’s meeting of the European Society for Medical Oncology were more disappointing. Of 29 patients with advanced colorectal cancer treated with AMG 510 in Amgen’s Phase 1 clinical trial, one patient showed partial tumor shrinkage. That’s a response rate of 3%.